Loiasis Clinical Trial
— EOLoaOfficial title:
Randomized Clinical Trial, Double-blind, Dose-escalating of Drug Intensities, Evaluating the Safety and Efficacy of Levamisole in Loa Loa Microfilaremic Patients
This study aims at evaluating the safety and efficacy of levamisole in patients with loiasis infection.
Status | Completed |
Enrollment | 255 |
Est. completion date | July 15, 2021 |
Est. primary completion date | April 24, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Written consent written, signed (or with thumbprint) and dated - Aged 18 to 65 inclusive - Individual microfilarial density = 1mf/mL - Body weight = 40 kg in women and = 45 kg in men; and less than 85 kg - In good health condition, as determined by the medical questionnaire and the general clinical examination: absence of acute or chronic infection Exclusion Criteria: - Participation in any study other than purely observational, in the 4 weeks preceding this study (determined by the theoretical date of administration of LEV or placebo). - Any vaccination in the 4 weeks preceding this study. - Acute infection requiring a treatment in the 10 days preceding this study, determined by the anamnesis during the medical interview (example: pulmonary infection, ENT, digestive, cutaneous, with implementation of an antibiotic treatment or not) - Warfarin treatment - Treatment with clozapine, phenythiazines, sulfasalazine, carbamazepine, synthetic antithyroid, ticlopidine, cimetidine, and gold salts: whether it is a long-term treatment, or a treatment given in a single dose 10 days before the start of treatment for the clinical trial (precaution of use compared to the risk of agranulocytosis of immuno-allergic or toxic origin) - Known immunosuppressive pathology - Past or current history of neurological (including epilepsy) or neuropsychiatric disease - History of agranulocytosis - Consumption of alcohol, taking cocaine or other drugs of abuse in the 72 hours preceding the administration of the treatment of the test determined by the anamnesis during the medical interview - Any condition, in the opinion of the investigator, which exposes the subject to an undue risk - Known intolerance to levamisole - Subjects who gave blood in the 8 weeks before entry into the study, with a standard volume (> 500 mL) - During the clinical examination: symptoms, physical signs or biological constants suggestive of systemic disorders, including renal, hepatic, cardiovascular, pulmonary, cutaneous, immunodeficiency, psychiatric disorders and other abnormalities likely to interfere with the interpretation results of the test. The doctor may then give a favorable or unfavorable opinion for the inclusion of the participant - Taking IVM and / or LEV during the last six months; and / or mebendazole or albendazole in the last month - Pregnant and lactating women (based on self-declaration) |
Country | Name | City | State |
---|---|---|---|
Congo | Secteur opérationnelle de la Santé, Ministère de la Santé et de la Population | Sibiti |
Lead Sponsor | Collaborator |
---|---|
Programme National de Lutte contre l'Onchocercose, Republic of the Congo |
Congo,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety and tolerability of levamisole | Absence of severe adverse events during the first week | 1 week | |
Primary | Incidence of adverse events with levamisole | Proportion of adverse events during the first week | 1 week | |
Secondary | Efficacy of levamisole | Proportion of reduction of the microfilarial density of Loa loa at Day 2, Day 7, and Month 1 | Day 2, Day 7, and Month 1 | |
Secondary | Proportion of individuals without microfilariae of Loa loa | Proportion of individuals with a diminution of 40% and 80% and more of the microfilarial density at Day 7 and Month 1 | Day 7 and 1 Month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02644525 -
Efficacy and Microfilaricidal Kinetics of Imatinib for the Treatment of Loa Loa
|
Phase 2 | |
Not yet recruiting |
NCT04035174 -
Evaluation of the Diagnosis Performances of DEC LTS-2 Skin Patch for Onchocerciasis in Central Africa
|
N/A | |
Completed |
NCT05085665 -
Loiasis Cross-reactive Antigenemia and Treatment-related Adverse Events
|
Phase 4 | |
Active, not recruiting |
NCT04258670 -
Spontaneous Antigenemia in Loiasis
|
||
Active, not recruiting |
NCT04049851 -
Clinical Trial Evaluating the Safety and Efficacy of Moxidectin 2 mg Ivermectin-controlled in Loa Loa Microfilaremic Patients
|
Phase 2 | |
Not yet recruiting |
NCT06350851 -
Development of a New Rapid Diagnostic Test to Support Onchocerciasis Elimination
|
N/A | |
Completed |
NCT01111305 -
Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis
|
Phase 2 | |
Not yet recruiting |
NCT06252961 -
A 3- to 5-day Clinical Trial of Levamisole in Loiasis Infected Subjects
|
Phase 2/Phase 3 |